Clinical Perspectives of Gut Microbiota in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: Where Do We Stand?

Abstract

The gut microbiota (GM) plays a vital role in human health, with increasing evidence linking its imbalance to chronic kidney disease and end-stage kidney disease. Although the exact methods underlying kidney-GM crosstalk are not fully understood, interventions targeting GM were made and lay in three aspects: diagnostic, predictive, and therapeutic interventions. While these interventions show promising results in reducing uremic toxins and inflammation, challenges remain in the form of patient-specific GM variability, potential side effects, and safety concerns. Our understanding of GMs role in kidney disease is still evolving, necessitating further research to elucidate the causal relationship and mechanistic interactions. Personalized interventions focusing on specific GM signatures could enhance patient outcomes. However, comprehensive clinical trials are needed to validate these approaches' safety, efficacy, and feasibility.

• Authors: Alexandru Cosmin Pantazi, Mustafa Ali Kassim Kassim, Wassan Nori, Liliana Ana Tuta, Cristina Maria Mihai, Tatiana Chisnoiu, Adriana Luminita Balasa, Larisia Mihai, Ancuta Lupu, Corina Elena Frecus, Vasile Valeriu Lupu, Sergiu Ioachim Chirila, Anca Gabriela Badescu, Laurentiu-Tony Hangan, Simona Claudia Cambrea
• Journal: Biomedicines (Biomedicines) Vol. 11 Issue 9 (Sep 07 2023) ISSN: 2227-9059 [Print] Switzerland
• PMID: 37760920 (Publication Type: Journal Article, Review)